FDA Approved Indications for this Orphan Drug:Treatment of adults (>18 years old) with metastatic renal cell carcinoma.
FDA Marketing Approval issued as of:
Orphan Drug exclusivity ends on:
Company Making and Marketing this drug:
FDA Designation Date:
FDA Drug Designation:
Treatment of metastatic renal cell carcinoma.